SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

BioXcel Therapeutics Announces First Patient Enrolled In Phase 1b/2 Study Of BXCL501 For Acute Treatment Of Agitation Associated With Dementia

Foundational study with plans to address multiple types of agitation associated with dementia Expands the potential therapeutic use of BXCL501 beyond neuropsychiatric disorders Topline results expected in

Benzinga · 01/07/2020 12:15

Foundational study with plans to address multiple types of agitation associated with dementia

Expands the potential therapeutic use of BXCL501 beyond neuropsychiatric disorders

Topline results expected in mid-2020

NEW HAVEN, Conn., Jan. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that the first patient has been enrolled in a Phase 1b/2 study of BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine (“Dex”), for the acute treatment of agitation in patients with dementia.